JERSEY CITY, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and ...
DURHAM, N.C.--(BUSINESS WIRE)--Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by ...
ReSTORE trial met both primary endpoints and demonstrated non-inferiority of rezafungin versus current standard of care, caspofungin1 Rezafungin demonstrated high mycological efficacy rates in initial ...
Please provide your email address to receive an email when new articles are posted on . Oteseconazole, an investigational oral antifungal therapy, was shown to be safe and effective in the treatment ...
JERSEY CITY, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results